Ocular Therapeutix, Inc. OCUL
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- -41.19%
- 1 year
- -34.50%
- Market cap
- 1.57B
- Revenue (ttm)
- 52.05M
- EPS (ttm)
- -1.40
- Shares out
- 219.62M
- Forward P/E
- -4.82
- YTD return
- -41.19%
- 1-year return
- -34.50%
- Volume
- 3.36M
- Avg volume
- 3.04M
- Open
- 7.09
- Previous close
- 6.82
- Day's range
- 6.83 – 7.17
- 52-week range
- 6.00 – 16.44
- Beta
- 1.22
- Analysts
- Strong Buy
- Price target
- 25.45 (+256.5%)
- Earnings date
- Nov 9, 2026
5D -0.33 (-4.44%)
Key statistics
- Enterprise value
- 978.52M
- PEG ratio
- 0.00
- Price / sales
- 30.12
- Price / book
- 3.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.10%
- Free cash flow
- -159.25M
- Total cash
- 598.64M
- Total debt
- 79.38M
- Return on equity
- -72.99%
- Short % of float
- 15.46%
- 50-day average
- 8.65
- 200-day average
- 9.07
Analyst view
Consensus: strong buy
- Target (low)
- 14.00
- Target (mean)
- 25.45
- Target (high)
- 34.00
- Strong buy4
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.3548.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.36348 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | -0.39545 | -0.35 | +0.05 | +11.49% |
| May 5, 2026 | Mar 31, 2026 | -0.32 | -0.41 | -0.09 | -28.12% |
| Feb 5, 2026 | Dec 31, 2025 | -0.33 | -0.29 | +0.04 | +12.12% |
| Nov 4, 2025 | Sep 30, 2025 | -0.39 | -0.37 | +0.02 | +5.13% |
| Aug 5, 2025 | Jun 30, 2025 | -0.35 | -0.39 | -0.04 | -11.43% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | Needham | reit | Buy | Buy |
| Oct 12, 2026 | UBS | init | — | Buy |
| Oct 2, 2026 | Chardan Capital | main | Buy | Buy |
| Sep 29, 2026 | Needham | reit | Buy | Buy |
| Sep 16, 2026 | Chardan Capital | main | Buy | Buy |
| Sep 16, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ocutx.com
News
Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026 
Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences 
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target 
UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14 
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
Your note
Sign in to keep a note on OCUL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERMAN TODD | Officer | Sale | Oct 7, 2026 | 140,484 |
| DUGEL PRAVIN U | Chief Executive Officer | Stock Gift | Aug 24, 2026 | 0 |
| HEIER JEFFREY S. | Officer | Sale | Oct 1, 2026 | 307,457 |
| KAISER PETER KAZUO | Officer | Sale | Oct 1, 2026 | 254,388 |
| LINDSTROM RICHARD L | Director | Stock Award(Grant) | Jun 9, 2026 | 260,933 |
| MEYERS STEVE LAWRENCE | Officer | Stock Award(Grant) | Jan 1, 2026 | 217,628 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.96% | 32,844,043 | 234.51M | Jun 29, 2026 |
| Deep Track Capital, Lp | 8.96% | 19,686,282 | 140.56M | Jun 29, 2026 |
| Blackrock Inc. | 8.82% | 19,376,555 | 138.35M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 5.71% | 12,540,000 | 89.54M | Jun 29, 2026 |
| Summer Road LLC | 5.56% | 12,208,296 | 87.17M | Jun 29, 2026 |
| Venrock Adviser, LLC | 4.71% | 10,346,926 | 73.88M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.42% | 9,704,363 | 69.29M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 6,616,995 | 47.25M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.53% | 5,562,722 | 39.72M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.23% | 2,700,674 | 19.28M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.19% | 2,611,078 | 18.64M | Aug 30, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.03% | 2,261,254 | 16.15M | Aug 30, 2026 |